Home HOME Neoplasma 2011 Neoplasma Vol.58, No.2, p.172-178, 2011

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.58, No.2, p.172-178, 2011

Title: Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer
Author: E. VRDOLJAK, M. BOBAN, T. OMRCEN, D. HREPIC, V. FRIDL-VIDAS, L. BOSKOVIC

Abstract: Optimal first-line chemotherapy for metastatic breast cancer (MBC) is challenging, particularly in patients previously treated with (neo) adjuvant anthracyclines/taxanes. Based on preclinical synergy with mitomycin C (MMC) and capecitabine in human tumor xenografts, we conducted a phase II study of first-line capecitabine and MMC in MBC. Patients received 3-weekly chemotherapy comprising MMC 8 mg/m2 day 1 and capecitabine 1000 mg/m2 twice daily, days 1-14. Combination chemotherapy was administered for a maximum six cycles, single-agent capecitabine could be continued until progressive disease or unacceptable toxicity. Thirty patients were included, objective response rate was 65.5%. After a median follow-up of 18.5 months, median time to progression was 8.5 months and median overall survival was 29.8 months. The main adverse events were thrombocytopenia, pneumonitis and hemolytic uremic syndrome. Our data suggest that first-line capecitabine and MMC has good antitumor activity in MBC, but is associated with MMC-specific toxicity.

Keywords: metastatic breast cancer; capecitabine; mitomycin C; chemotherapy
Year: 2011, Volume: 58, Issue: 2 Page From: 172, Page To: 178
doi:10.4149/neo_2011_02_172
Price: 16.80 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.